Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Aeterna Zentaris stock opened at $3.70 on Monday. The firm has a market cap of $6.63 million, a PE ratio of -0.25 and a beta of 1.55. Aeterna Zentaris has a 12 month low of $3.96 and a 12 month high of $12.00. The stock’s 50 day simple moving average is $4.70 and its two-hundred day simple moving average is $6.30.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.